MRI-Guided Adaptive Radiation Therapy for Oligometastatic Prostate Cancer Involving the Adrenal Gland: A Case Report and Literature Review.

IF 0.7 Q4 ONCOLOGY

Case Reports in Oncology Pub Date : 2025-04-19 eCollection Date: 2025-01-01 DOI:10.1159/000545983

Fabian J Bolte, Christopher K Luminais, Matthew Mistro, Michael E Devitt

{"title":"MRI-Guided Adaptive Radiation Therapy for Oligometastatic Prostate Cancer Involving the Adrenal Gland: A Case Report and Literature Review.","authors":"Fabian J Bolte, Christopher K Luminais, Matthew Mistro, Michael E Devitt","doi":"10.1159/000545983","DOIUrl":null,"url":null,"abstract":"Introduction: Metastasis-directed therapy is an evolving treatment modality for patients with oligometastatic prostate cancer. Although the microenvironment of the adrenal glands is enriched in androgen precursors, isolated adrenal metastases are rare. The application of stereotactic ablative radiotherapy (SBRT) to oligometastatic adrenal lesions has been limited due to toxicity concerns.Case presentation: We report a patient with castration resistant prostate cancer and oligometastatic disease recurrence to the adrenal gland who underwent MRI-guided adaptive radiotherapy, which allowed accurate delivery of SBRT while minimizing exposure to adjacent radiosensitive organs. This approach was safe and resulted in long-term local and systemic disease control.Conclusion: This case highlights the potential role for MRI-guided SBRT in selected patients with oligometastatic prostate cancer to the adrenal glands.","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"638-645"},"PeriodicalIF":0.7000,"publicationDate":"2025-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12119076/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000545983","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Metastasis-directed therapy is an evolving treatment modality for patients with oligometastatic prostate cancer. Although the microenvironment of the adrenal glands is enriched in androgen precursors, isolated adrenal metastases are rare. The application of stereotactic ablative radiotherapy (SBRT) to oligometastatic adrenal lesions has been limited due to toxicity concerns.

Case presentation: We report a patient with castration resistant prostate cancer and oligometastatic disease recurrence to the adrenal gland who underwent MRI-guided adaptive radiotherapy, which allowed accurate delivery of SBRT while minimizing exposure to adjacent radiosensitive organs. This approach was safe and resulted in long-term local and systemic disease control.

Conclusion: This case highlights the potential role for MRI-guided SBRT in selected patients with oligometastatic prostate cancer to the adrenal glands.

查看原文本刊更多论文

mri引导下的适应性放射治疗累及肾上腺的少转移性前列腺癌1例报告及文献复习。

转移导向治疗是一种针对少转移性前列腺癌患者的不断发展的治疗方式。虽然肾上腺的微环境富含雄激素前体，但孤立的肾上腺转移是罕见的。立体定向消融放疗（SBRT）在肾上腺少转移性病变中的应用由于毒性问题而受到限制。病例介绍：我们报告了一位去势抵抗性前列腺癌和肾上腺少转移性疾病复发的患者，他接受了mri引导的适应性放疗，该放疗可以准确地传递SBRT，同时最大限度地减少对邻近放射敏感器官的暴露。这种方法是安全的，并导致长期的局部和全身疾病控制。结论：该病例强调了mri引导下的SBRT在肾上腺转移性前列腺癌患者中的潜在作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊